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Effects of Six Antimicrobial Drugs on Rat Intestinal 
Flora: Is the Rat Model of Predictive Value in Clinical 
Practice? 
E. BERTAZZONI MINELLI* and A. BENIN1 
Institute of Pharmacology, University of Verona, Policlinico Borgo Roma, 37134 Verona, Italy 
Received 1 September 1992; revised 10 February 1993 
The effects of six antimicrobial agents on rat intestinal microflora after oral and/or parenteral administration were 
studied in parallel. Antimicrobial drugs were administered by the oral (norfloxacin, pefloxacin, ciprofloxacin) and 
parenteral routes (pefloxacin, imipenem, aztreonam, teicoplanin) at the doses used in clinical practice. Faecal 
specimens were collected before and after two, four, seven or 1 1 treatments. Qualitative and quantitative determination 
of flora composition was performed using a modified version of standard methods. Fluoroquinolones reduced the 
levels of enterobacteria, while gram-positive bacteria (enterococci, staphylococci, lactobacilli) were little affected. 
Comparable effects were observed after intraperitoneal and oral administration of pefloxacin. The changes induced 
by fluoroquinolones on intestinal flora showed a uniform trend: certain differences may be ascribed to different 
pharmacokinetic properties such as bioavailability and melabolism. lmipenem caused a significant decrease in mean 
concentrations of E.  coli, clostridia and fungi. Aztreonam induced a prompt and marked inhibition of E. coli and 
Proteus spp., while prolonged treatment induced an overgrowth of fungi and bacteroides. Teicoplanin caused a 
significant decrease in the levels of clostridia and anaerobic lactobacilli. Irregular concentrations of all drugs, with great 
intersubject variability, were detected at  different times. These results are comparable to those observed in humans. The 
potential of an antimicrobial agent to  change the intestinal microflora is related to its antibacterial activity, route of 
administration and pharmacokinetic properties. The parenteral route induced changes in the intestinal ecosystem, as 
did oral administration. The rat appears to be a useful experimental model for studying the effects of antimicrobial 
drugs on intestinal flora. 
KEY WORDS-Intestinal microflora; Antibiotics; Fluoroquinolones; Imipenem; Teicoplanin; Aztreonam; Rat. 
INTRODUCTION 
There is increasing recognition of the importance 
of the microbial flora as a reservoir of potential 
pathogens, and iatrogenic changes in intestinal 
microecology have been considered as being of 
clinical importance. Although interpersonal vari- 
ations exist, the intestinal ecosystem has a stable 
composition.' 
The faecal flora can be altered by various factors, 
but pathological conditions and antimicrobial 
chemotherapy22,26 induce profound and rapid 
changes. The imbalance of the ecosystem following 
the administration of antimicrobial agents may 
entail other consequences such as new colonisation 
or overgrowth of naturally non-sensitive micro- 
organisms (Enterobacteriaceae, fungi, staphylo- 
cocci) o r  the development of resistance among 
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constituents of the normal flora: in brief, the 
phenomena that occur in impaired colonisation 
resistance." 
The extent of these changes depends on the anti- 
microbial properties, pharmacokinetic character- 
istics and route of administration of the drug. 1 0 , 2 2  
Parenteral administration is considered more spar- 
ing of the intestinal microflora than oral adminis- 
tration2' Following oral administration, a large 
amount of drug may remain in the gut depending 
on its bioavailability, while, after parenteral 
administration, antimicrobial agents may reach 
the intestinal tract by hepatobiliary excretion or 
transintestinal e l i m i n a t i ~ n . ~ ~ . ~ ~  
We studied the effects of different antimicrobial 
drugs in parallel on rat intestinal microflora after 
oral and/or parenteral administration. Six anti- 
biotics were chosen according to their antimicrobial 
properties and pharmacokinetic characteristics: 
54 
aztreonam and teicoplanin were included in the 
study owing to their selective narrow antimicrobial 
spectrum against aerobic gram-negative micro- 
organisms and gram-positive cocci, respectively; 
imipenem was studied because of its broad spectrum, 
high activity and parenteral route of administration; 
fluoroquinolones (norfloxacin, ciprofloxacin and 
pefloxacin) were studied as chemically related 
compounds with similar antimicrobial activity and 
different pharmacokinetic  characteristic^.'^ Pefloxa- 
cin was administered both orally and parenterally 
for the purposes of directly comparing the influence 
of the route of administration. 
The study was conducted in the rat, whose intes- 
tinal flora composition may be partly considered 
similar to that of man. The aim was to assess 
whether the rat model may be of predictive value in 
human studies. 
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METHODS 
Animals and treatments 
Thirty-five outbred female Wistar rats, 5-6 wk 
old and weighing 140-160g, were obtained from 
Morini (Parma, Italy). The rats were housed under 
conventional conditions in a temperature (2 1 f 2°C) 
and humidity (55 k 5 per cent) controlled room with 
12 h light/dark cycle (light on from 06.00 to 18.00 h) 
and kept there for 1 wk before use. The animals were 
fed with commercial rat pellets (MIL, Morini, Italy) 
and water ad libitum. All rats were housed in groups 
of five in macrolon cages on sawdust. No special 
measures were taken to prevent coprophagia. 
Rats were divided into seven groups and treated 
with the following drugs at the dosages indicated: 
( I )  norfloxacin, 10 mg/kg/d, p.0. (Merck-Sharpe & 
Dohme, Rome); (2) ciprofloxacin, 8 mg/kg/d, p.0. 
(Bayer, Milan, Italy); (3) perfloxacin, 10 mg/kg/d, 
p.0.; (4) pefloxacin, 10 mg/kg/d, i.p. administration 
(Rh6ne-Poulenc, Milan, Italy); ( 5 )  imipenem- 
cilastatin, 10-10 mg/kg/d, i.m. injection, (Sigma- 
Tau, Pomezia, Italy); (6) aztreonam, 100 mg/kg/d, 
i.m. (Menarini, Florence, Italy); (7) teicoplanin, 
8 mg/kg/d, i.m. (Lepetit, Milan, Italy). 
Solutions were prepared fresh each day by 
dissolving the drugs in saline, according to the 
manufacturer’s instructions. 
All drugs were administered once daily in the 
morning by gastric intubation (gastric needle-tube) 
(10 ml/kg body weight) or by parenteral injection 
(1 ml/kg body weight) for a period of 8-12 d (except 
Sundays). The doses of antimicrobial drugs corres- 
ponded, on a body weight basis, to the doses 
administered to patients with mild infections in 
normal clinical practice. 
Samples 
Four to five fresh faecal pellets were taken 
aseptically at emission from each rat in the morning 
before drug administration. Faecal samples were 
placed in sterile tightly capped vials and processed 
immediately. Specimens were collected before (con- 
trol) and after two, four, seven and 11 treatments as 
well as 18 d after the end of drug administration: 
each rat was therefore used as its own control. 
Culture methods 
Quantitative and qualitative analysis of faecal 
flora was carried out using a modified version3 of 
standard techniques. 5 , 2 8  
Sterile virology Plexiglas plates with 80 wells 
(8 x 10, diameter 16 mm, 1 ml volume) were used 
instead of Petri dishes. Each well was filled with 
0.5ml of the medium. This rapid, accurate tech- 
nique, which is a simplified micromethod previously 
described in detail,’ allows a saving of time and 
materials, and yields qualitative and quantitative 
results comparable to those obtained with the more 
expensive standard techniques (Petri dishes, etc.). 
One gram of faeces from each rat was suspended 
by manual homogenisation in 9 ml prereduced 
sterile saline and filtered through gauze, whereafter 
serial ten-fold dilutions were made from lo-’ 
through lo-”  in the same fluid. Samples (10~1) 
from each dilution were seeded on the surface of 
selective and non-selective culture media prepared 
in the Plexiglas plates; the same sample was assayed 
simultaneously on the following 15 media (from 
Difco Laboratories, Detroit, USA unless otherwise 
specified): blood agar for total aerobes and 
anaerobes; Schaedler agar (total anaerobes); kana- 
mycin (1 2 mg/l)-vancomycin (20 mg/l)-Schaedler 
agar (bacteroides); Reinforced Clostridial agar 
(clostridia); Clostridium dificile selective agar 
(Oxoid); Phenylethyl alcohol agar (PEA, Oxoid, 
gram-positive anaerobic cocci); Mitis Salivarius 
agar (aerobic and anaerobic cocci); Tomato juice 
agar and Rogosa SL agar (bifidobacteria, aerobic 
and anaerobic lactobacilli); Bile esculine azide agar 
(enterococci); Mannitol salt agar (staphylococci); 
McConkey agar and SS agar (Enterobacteriaceae); 
Littman oxgall agar and Sabouraud dextrose agar 
(yeasts). Duplicate samples of 0.1 ml of the original 
I /I0 suspension of faeces were seeded on blood agar 
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solidified in Petri dishes. All steps of the micro- 
biological assay were carried out in an anaerobic 
box (95 per cent C0,-5 per cent H, atmosphere). 
The aerobic plates were incubated at 37°C for 24 h 
and anaerobic plates for 48-72 h in an anaerobic 
chamber (Heraeus) in an 85 per cent N,-10 per cent 
C0,-5 per cent H, atmosphere, at  negative pressure 
(400 Torr). After incubation, different colony types 
were counted, from both aerobic and anaerobic 
plates. 
We considered as positive the last well presenting 
growth of at least three colonies. The number of 
wells showing the growth of bacteria indicated the 
logarithm of the concentration of microorganisms 
per gram of faeces (quantitative determination). 
Thereafter, the morphologically distinct colonies 
were isolated in pure culture and identified by 
standard methods on the basis of Gram-stain and 
morphological and biochemical analysis (API 
System S.A., La Balme Les Grottes, France). 
Enterobacteriaceae were identified using an API 20 
E test-kit system; streptococci by API 20 Strep; 
staphylococci by API Staph; fungi by API C AUX, 
and anaerobes by the Rap ID ANA System. The 
lowest detectable number of organisms is 2.0 log,, 
of the number of bacteria per gram of faeces. 
Results are expressed as mean log,, viable 
organisms per gram sample+ standard deviation of 
the mean. 
Faecal samples were tested for the presence of 
C. perfringens enterotoxins by the reversed passive 
latex agglutination test (Oxoid PET RPLA).' 
C .  dificile cytotoxin was assayed by inoculating 
fixed dilutions (in PBS) of stool filtrates into 
96-well microdilution plates seeded with HeLa cells, 
incubated overnight and read after 24 h. Positive 
samples were confirmed by neutralisation with a 
specific antitoxin.' 
Student's t-test was used for comparison of 
mean values. A probability level of P<O.O5 was 
considered significant. 
5 5  
Antibiotic concentration in,faeces 
The concentrations of antibiotics in faeces were 
determined on the first dilution of the samples used 
for the microbiological determination. 
Samples of faeces of rats treated with imipenem 
were immediately stabilised by addition of an 
equal volume of MES (morpholinethan-sulphonate 
buffer, pH 6 )  plus ethylene glycol (1 : 1 mixture)23 in 
order to reduce possible degradation of the drug. 
The samples were centrifuged and the assay carried 
out on supernatant using the agar well diffusion 
microbiological method. The media, test micro- 
organisms and final concentration of inoculum are 
listed in Table 1. The assay plates (24 x 24 cm, 
Bioassay, Nunc, Denmark) were overlaid with 
different agar media. After solidification, 8 mm 
diameter wells were punched out of the agar 
medium and filled with 50pl of supernatant. 
Appropriate standard concentrations of each drug 
were prepared in sterile phosphate-buffered saline 
(pH = 7). Imipenem dilutions were obtained in 
MES-ethylene glycol. All samples were assayed in 
triplicate. After overnight incubation at 37"C, the 
inhibition zones were measured. The antibiotic 
concentrations in the faeces were determined by 
comparison with results obtained with the antibiotic 
standards and were expressed as pg of antibiotic per 
g faeces. 
RESULTS 
Effects of drugs on intestinal microflora ojrats 
The quantitative effects of different antibiotics on 
rat faecal flora composition are summarised in 
Tables 2-5, while qualitative changes are shown in 
Table 6. In the figures, the results are expressed as 
the difference in mean values vs controls, where each 
column represents the positive or negative effects 
of antibiotic treatments on colonic microflora in 
comparison to the mean count values determined 
before drug administration (baseline = time 0). 
Each animal is its own control, i.e. the composition 
of the flora was followed up in each animal before, 
during and after the end of treatment. 
We noted a number of variations in the faecal 
flora of rats in pretreatment samples, fungi being 
predominant and the levels of bacteroides and 
bifidobacteria very low. This composition was 
different from that of animals utilised in other 
experiments, obtained from the same breeders and 
of the same species, sex, age, weight, etc., and main- 
tained in the same standard housing conditions. 
Each rat was assigned to different groups on the 
basis of the faecal composition analysis done before 
drug administration, and therefore each group 
showed the same rate of variability. We decided to 
perform these experiments because this condition 
may reflect the sample variability in human practice. 
All treatments induced the disappearance of 
gram-positive non-spore-forming rods, namely 
bifidobacteria. 
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Table 1. Microbiological assay of antimicrobial drugs: media, microorganisms, and 
inoculum concentrations 
Medium Test Inoculum* 
Drugs (agar) microorganisms (ml/ 100 ml agar) 
Aztreonam Antibiotic 
Medium I 
(Difco) 
(Oxoid) 
(Oxoid) 
(Oxoid) 
(Oxoid) 
Ciprofloxacin Isosensitest 
Pefloxacin Isosensitest 
Norfloxacin Isosensitest 
Teicoplanin Isosensitest 
Imipenem Brain-Heart Agar 
(Difco) 
E. coli 
SC 12155 
0.15 
E. coli 0-50 
ATCC 25922 
E. coli 0.15 
Kp 05124 
E. coli 0.10 
Kp 05124 
B. subtilis 0.02 
ATCC 6633 
(Spore suspension; Difco) 
B. subtilis 0.02 
ATCC 6633 
(Spore suspension; Difco) 
*Inoculum from 18 h culture. 
Fluoroquinolones 
intestinal flora showed a uniform trend. 
The changes induced by fluoroquinolones on 
Norfloxacin (Table 2) .  Norfloxacin caused signifi- 
cant inhibition of Escherichia coli, yeasts, total 
anaerobes, clostridia and anaerobic lactobacilli 
after two and four treatments. After 1 wk of treat- 
ment E. coli and anaerobic lactobacilli continued to 
be inhibited. It is interesting to note the substantial 
decrease in levels of fungi (5 log) after two and 
four administrations of norfloxacin. Bacteroides, 
enterococci and anaerobic cocci were not affected 
by norfloxacin treatment (Figure I). 
Ciprofloxacin (Table 2 ) .  Four treatments with 
ciprofloxacin caused significant inhibition of E. coli 
( 4 5  log), yeasts, bacteroides, clostridia, anaerobic 
lactobacilli and cocci. After 1 wk of treatment these 
effects were still observable for Enterobacteriaceae, 
while yeasts and most components returned to 
normal values (Figure 1). Prolonged administration 
(1 1 treatments) caused an increase in yeasts, 
bacteroides and clostridia compared to mean values 
determined before drug administration. 
Group D streptococci were little affected by 
treatment with ciprofloxacin at any of the times 
considered. 
Pefloxacin. The oral administration of pefloxacin 
caused strong inhibition of E. coli and yeasts at all 
times; enterococci increased (Table 3). These effects 
were comparable to those observed after intra- 
peritoneal administration of the drug. Pefloxacin, 
administered by the parenteral route, induced 
marked changes at the beginning of treatment (2 
days). The modifications corresponded to high con- 
centrations of drug in stools. Staphylococci were 
also inhibited. After 1 wk of treatment the behav- 
iour was similar in both groups of rats treated via 
the different routes (Figure 1). 
Pefloxacin, ciprofloxacin and norfloxacin 
induced comparable quantitative changes (Figure 
1 )  as well as changes in the bacterial species. The 
administration of all fluoroquinolones caused the 
disappearance of Btjidobacterium spp. and E. coli 2 
(a biotype frequently isolated), as well as other 
changes shown in Table 6 .  Among the enterococci, 
we frequently found E. faecalis instead of 
E. faecium. 
Imipenem (Table 4)  
Imipenem confirmed its broad spectrum of 
activity against intestinal flora. After two treat- 
ments, imipenem caused a significant decrease in 
mean counts of E. coli (4 log), clostridia (6 log), total 
anaerobic count and fungi. Enterococci were also 
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Table 5. Effect of i.m. administration of teicoplanin (8 mg/kg/d) on faecal flora during treatment 
and 18d after end of treatment. Results are expressed as log,o no. bacteria/g fresh faeces 
(mean f SD, n = 5). Antibiotic concentrations in stool (pg/g) are included 
Micro 
organisms 
E. coli 
P .  mirabilis 
Enterococci 
Staphylococci 
Lactobacilli 
Fungi 
Total anaerobes 
Bacteroides 
Clostridia 
AnO, lactobacilli 
AnO, cocci 
Drug cone. (Pg/g) 
Treatments (no.) 
18 d after 
0 2 4 7 treatment 
8.0 f 3.0 
2.0 f 0.0 
5.4f0.5 
3.0 f 0.0 
4.0 f 0.0 
8.0 f 3.0 
I 1.8 f0.4 
3.4f0.5 
12.0 f 0.0 
7.8 f 1 .O 
4.2 f 0.4 
6.0 k 1.2 
2.0 * 0.0 
5.8 k0.8 
2.3 f0.5** 
3.6 k 0.9 
7.0 f 2.8 
7.8 f 2. I ** 
3.6f 1.1 
4.2 f 0.4** 
5.0 k 1.9* 
4.6 f 0.4 
5.8 f 0.8 
2.0 f 0.0 
5.4 f 0.5 
3.0 f 0.0 
5.4f2.3 
5.8& 1.1 
6.0 2.3** 
4.0 f 0.7 
4.2 f 0.8** 
4.4 f 0.9** 
6.0 f 1.2* 
9.0 f 1-0 
2.6 f 0.9 
5.2 f 0.4 
3.0 f 0-0 
3.0 f 0.0 
9.4 f 0.9 
9.4f 1-3** 
4.8 f 0.4 
5.4 f 0.5** 
4.4 f 0.5** 
4.8 f 0.8 
0 0 1.3 f 0-2 
(3/5) 
5.6f0.5 
2.6 f 0.9 
6.2 f 0.4 
2.8 0.4 
4.2 f 0.4 
5.6f 1.1 
4.7f0.9** 
3.6 f 0.5 
5.0f0.7** 
7.2 f 2.2 
5.2f1.1 
Significance: *P<O.O5; **P<O.O1 versus control. Student’s f test. 
Figures in parentheses are no. of positive samples/total no. of rats. 
inhibited, while bacteroides increased. These effects 
were maintained throughout the treatment (Figure 
2) .  We observed new colonisation by Proteus 
penneri instead of P .  mirabilis, which is a constant 
and normal component of rat intestinal flora. 
Imipenem induced no qualitative changes in the 
clostridia. At the end of treatment, when yeasts were 
present in normal levels, we isolated ascospores of 
the Candida genus. 
Aztreonam (Table 4 )  
The administration of aztreonam, a selective 
agent against gram-negative aerobic bacteria, 
caused a marked, prompt inhibition of E. coli (2-3 
log) and Proteus spp. This effect was maintained 
throughout the treatment and 18 d after the end of 
drug administration. We also observed an initial 
decrease in the number of anaerobes which returned 
to normal values in the course of treatment. 
After 11 treatments there was a significant 
increase (P<O.Ol) in fungi levels (3 log) and 
overgrowth of bacteroides (6 log) (Figure 2) .  
Aztreonam caused the disappearance of all the 
most common Enterobacteriaceae including E. coli 1 
and E.  coli 2 ,  but selected potentially pathogenic 
microorganisms such as Klebsiella pneumoniae, K. 
oxytoca, Morganella morganii and Shigella sonnei. 
Teicoplan in 
Teicoplanin showed marked inhibition of 
clostridia and anaerobic lactobacilli as reported 
in Table 5. This significant inhibitory effect was 
maintained in the course of seven treatments. 
Staphylococci were slightly affected after two 
treatments only, while the mean enterococci count 
was unaltered (Figure 2) .  However, among the 
enterococci, we observed a number of qualitative 
changes: E. faecalis, a major component of 
normal rat flora, was inhibited by teicoplanin, and 
E. faecium was isolated in the course of treatment. 
Moreover, teicoplanin caused disappearance of the 
gram-posi tive anaerobic non-spore-forming bacilli. 
Long-term efects 
Eighteen days after the end of treatment 
the concentrations of intestinal microflora were 
normalised in pefloxacin-treated rats, while in other 
groups the total anaerobe levels remained lower, 
including the concentrations of clostridia. The 
concentrations of fungi 18 d after the end of treat- 
ment were lower than those observed before drug 
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Table 6. Qualitative effects of antimicrobial treatments on the composition of rat faecal flora 
expressed as inhibition of the prevalent species and growth of new species isolated during 
treatments 
Microorganisms 
Antibiotic Inhibition 
Teicoplanin 
Imipenem 
Aztreonam 
Fluoroquinolones 
norfloxacin, 
pefloxacin 
Ciprofloxacin 
Bijidobacterium spp. 
Escherichia coli 2 
En terococcus f a e c a h  
Eubacterium limosum 
Clostridium perfringens 
Veilionella spp. 
Bacteroides levii 
Bijidobacterium spp. 
E. coli 2 
Bijidobacterium spp. 
E. coli 2 
E. coli 1 
Propionibacterium granulosum 
C.  tyrobutyricum 
C. fallax 
Bijidobacterium spp. 
E. coli 2 
E.  faecium 
P .  granulosum 
6. buccae 
C .  fallax 
C.  tyrobutyricum 
Bijidobacterium spp. 
E. coli 2 
P. granulosum 
C .  fallax 
C. tyrobutyricum 
Growth 
E. coli 2* 
E.faeciumt 
Actinomyces odontholyticus 
C .  limosum 
C.  cadaveris 
C. histolyticum 
E. coli 2% 
E. faeciumt 
Proteus penneri 
Candida spp. 
Kiebsiella oxytoca 
K .  pneumoniae 
Morganella morganii 
Shigella sonnei 
C. butyricum 
C. innocuum 
B. capillosus 
E. lentum 
P. acnes 
Veillonella spp. 
C. ramosum 
C. beijerinkii 
C. butyricum 
C. limosum 
C. histolyticum 
In addition in 
pefloxacin groups: 
K.  pneumoniae 
Fusobacterium necrogenes 
B. intermedius 
Streptococcus intermedius 
S. constellatus 
S. morbillorum 
E. limosum 
A .  israelii 
P. acnes 
C. rarnosum 
C.  beijkerinkii 
C .  butyricum 
*Isolated at the end of drug administration (seven treatments). 
?High frequency. 
administration, but these values correspond to 
normal levels in rats analysed in other experiments. 
Moreover, the qualitative changes shown in Table 6 
were maintained. Neither C. perfringens entero- 
toxins nor C .  dificile and its cytotoxins were 
found. 
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E.coli Proteus Entero Lacto Fungi 
cocci bacilli 
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Total Bacter. Clostridia Lacto Cocci 
count bacilli 
0 Pejloxacin ip 0 Pejloxacin po Ciprofoxacin No floxacin 
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Figure 1. Changes in faecal microflora composition of rats treated with pefloxacin (lOmg/kg/d, oral and i.p.), ciprofloxacin 
(8 mg/kg/d, oral) and norfloxacin (10 mg/kg/d, oral) after four and seven treatments. Results are expressed as the difference in mean 
log,, count values obtained during treatments vs mean count determined in the same rat before starting treatment (baseline = time 0) 
Antibiotic concentrations in faeces 
Following two treatments pefloxacin adminis- 
tered by the intraperitoneal route was present in 
faeces in appreciable concentrations (Table 3). After 
1 wk of treatment, all antibiotics were eliminated in 
faeces with the exception of aztreonam. Prolonged 
administration (1 1 days) also induced substantial 
faecal elimination of aztreonam (I 21.5 27.9 pg/g 
of faeces) and ciprofloxacin (1 1.9 & 6.7 pg/g). 
The presence of different antibiotics was 
irregular, with considerable intersubject variability, 
as shown by the numbers of positive samples. 
DISCUSSION 
The present work confirms that antimicrobial 
drugs may influence the intestinal microbial flora to 
different extents. 
The microflora changes were evident at the 
beginning of drug treatment: two administrations 
once daily induce early significant modifications 
which may progressively become more marked 
(imipenem and teicoplanin) or may revert to normal 
values in the course of treatment (ciprofloxacin). 
The effects induced by fluoroquinolones are 
representative for this class of antimicrobial drugs. 
Quantitative changes, such as a marked suppression 
of Enterobacteriaceae, were observed alongside 
qualitative modifications of other components of 
the intestinal microflora. E. coli 2, E. faecium, 
bifidobacteria and C .  tyrobutyricum disappeared 
and were replaced by new species, such as the poten- 
tial pathogens A .  israelii and B. intermedius. Certain 
differences in the intestinal effects of quinolones 
may be ascribed more to their pharmacokinetic 
properties than to their antimicrobial activity. 
For example, ciprofloxacin, a drug with good 
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E. coli Proteus Entero- Lucto- Fungi 
mirabilis cocci bacilli 
4 treatments 0 Aztreonam Teicoplanin Imipenem 
Total Bacter. Clostridia Lacto- Cocci 
count bacilli 
-8 
6 T  7 treatments 
4 
2 
0 
-2 
-4 
-6 
-8 
bioavailability and low hepatobiliary e x c r e t i ~ n , ~ ~ ~ ’  
showed good activity against gram-negative bacilli 
and did not cause any significant changes in the 
faecal concentration of enterococci or yeasts. 
Moreover, ciprofloxacin induced slight modifi- 
cations in anaerobic flora. Among the quinolones, 
ciprofloxacin seems to be more sparing of the 
intestinal ecosystem. Norfoxacin induced more 
evident changes than those observed with cipro- 
floxacin; we considered this effect to be a conse- 
quence of the lower bioavailability of the drug. The 
effects of pefloxacin were of the same order as those 
caused by norfloxacin. However, pefloxacin, which 
is a drug possessing good bioavailability, is partly 
secreted into the bile as parent drug and as 
metabolites, norfloxacin being the most active 
(30%).13 Therefore, from the point of view of the 
impact on the intestinal ecosystem, the different 
pharmacokinetic properties and metabolic path- 
ways of norfloxacin and pefloxacin are of little 
relevance. No significant differences were observed 
in antimicrobial activity against intestinal micro- 
flora between oral and parenteral administration 
of pefloxacin. The effects on faecal flora and its 
recovery in faeces are closely related to those 
described in humans after oral and parenteral 
admini~tration.~’ The faecal concentrations of 
quinolones were all in the same range after seven 
days of treatment. 
These results are in agreement with those 
observed in humans, as reported in a recent review 
by Nord and Edlund,” who concluded that ‘the 
administration of all quinolones caused a marked 
suppression or elimination of Enterobacteriaceae 
in humans, while enterococci and anaerobic 
micro-organisms were little affected’. 
Aztreonam and teicoplanin administered par- 
enterally induced changes in specific bacterial 
species, according to their respective antimicrobial 
activitie~.~,’ The aerobic gram-negative flora was 
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suppressed during treatment with aztreonam; the 
impact on anaerobic bacteria was variable depend- 
ing on the period of administration. Prolonged 
administration of aztreonam induced an over- 
growth of bacteroides and yeasts and corresponding 
high levels of the drug in the faeces. Aztreonam 
treatment in mice did not lead to complete eradi- 
cation of aerobic gram-negative rods in faeces.jO 
In our experiments most Enterobacteriaceae were 
inhibited, while M .  rnorganii and Klebsiella spp. 
appeared; complete eradication of these micro- 
organisms from the faeces could not be achieved in 
our rats. These data are similar, but not identical 
to those observed in patients." Cancer patients 
receiving 2 g  of aztreonam every 8 h  for 7-9d 
showed persistence of isolates of bacteroides and 
yeasts, but no overgrowth of these microorganisms. 
Teicoplanin induced a significant decrease in the 
number of clostridia; the concentrations obtained 
in faeces were lower than the minimum inhibitory 
concentrations for most cocci. These effects were 
comparable to those observed in humans treated 
with teicoplanin as perioperative prophylaxis in 
orthopaedic s ~ r g e r y . ~  Imipenem is highly active 
against gram-positive and gram-negative bacteria' 
and covers both aerobic and anaerobic components 
of the intestinal microflora. Although the faecal 
elimination is very low, imipenem induced constant 
minor changes in aerobic and anaerobic rat flora. 
These changes corresponded in terms of quality and 
intensity to those observed in patients treated with 
imipenem for surgical prophylaxis. " 
The imbalance of the intestinal flora observed 
during this study was evident in the course of the 
treatments but not severe, and C .  dificile was not 
isolated: I8 d after the end of drug administration 
the intestinal microflora became fairly normalised. 
These results provide further evidence that the 
parenteral route of administration, whether intra- 
peritoneal or intramuscular, can also induce signifi- 
cant disturbances in the intestinal microflora. In 
fact, the antimicrobial drugs may reach the intes- 
tinal contents via transintestinal secretion,24 blood 
diffusion, bile2' or lymphatic f l~ id . ' ' , ' ~ ,~ '  Even 
parenteral administration of antimicrobial drugs 
with a narrow spectrum and poor secretion into 
bileIg may induce modifications. Moreover, on 
increasing the duration of treatment these effects 
become more evident. The increase in faecal drug 
concentrations corresponded to a proportional 
inhibitory effect on the mean microbial concen- 
trations. Our method also allows discriminatory 
evaluation of the effects of chemically related 
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drugs, as shown by comparative analysis of the 
fluoroquinolones. We are also able to note 
changes in species of microorganisms whose mean 
concentrations are not affected, as occurs after 
administration of aztreonam against gram-positive 
non-spore-forming bacilli and teicoplanin against 
enterococci and bacteroides. 
Although the flora composition was unusual 
before treatments, these results obtained in rats are 
comparable to those reported in studies carried out 
in humans, as recently reviewed by Nord and 
Edlund.2Z Therefore, the experimental data may 
partly reflect what occurs in humans, namely 
the effects on the numbers and genera of micro- 
organisms. Among the different animal species, the 
rat may be considered the one with the intestinal 
flora closest to that of man in terms of composition, 
though not in terms of metabolic ~apac i ty . '~  The 
latter may be a factor influencing the antimicrobial 
activity of orally administered antibiotics, as well as 
the toxicological risk and/or inactivation of drugs, 
but the effects of antimicrobial drugs on the balance 
of the intestinal microflora are more important. We 
regard the rat as a useful experimental model for 
studying the effects of antimicrobial drugs on 
intestinal flora. New antimicrobial agents may be 
evaluated in the comparative and preliminary 
screening of efficacy, safety and intestinal side- 
effects. Basic antimicrobial screening models should 
include the effects on the intestinal ecosystem. These 
results render the rat model suitable for obtaining a 
rough estimate of new antibiotics and for making 
parallel comparisons between different drugs. 
Such studies may be of predictive value in clinical 
practice. 
(1) Changes in the intestinal microflora of the rat 
are: (i) similar for quinolones; (ii) selective for 
aztreonam and teicoplanin; (iii) also induced by 
parenteral administration. 
(2) Faecal concentrations of antibiotics increase 
with treatments. 
(3) Results in rats are comparable to those 
observed in humans. 
In conclusion: 
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